MAPT and Alzheimer disease: We demonstrate that blocking tau phosphorylation at AD-related Ser262/356 sites by introduction of the S2A mutation preferentially decreases the levels of taulower species and suppresses Aβ-mediated augmentation of tau toxicity (Fig 3).